Among these, ESR1 ligand-binding domain mutations are well recognized mechanisms of resistance to endocrine therapy, increasingly detected through circulating tumor DNA (ctDNA), leading to constitutive estrogen receptor activation and impacted endocrine sensitivity [38,39]. Here, ESR1 is linked to neoplasm.